{"nctId":"NCT00680953","briefTitle":"Denosumab Fracture Intervention Randomized Placebo Controlled Trial in Japanese Patients With Osteoporosis","startDateStruct":{"date":"2008-05"},"conditions":["Osteoporosis"],"count":1262,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Denosumab"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Alendronate sodium hydrate"]}],"interventions":[{"name":"Denosumab","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Alendronate sodium hydrate","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Involutional (postmenopausal and senile) osteoporosis with prevalent fragility vertebral fractures\n\nExclusion Criteria:\n\n* Any underlying condition,(other than BMD) that might have resulted in abnormal bone metabolism","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Incidence of New or Worsening Vertebral Fractures in Osteoporotic Subjects Treated With Denosumab Compared to Placebo","description":null,"paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"10.3","spread":null},{"groupId":"OG002","value":"7.2","spread":null}]}]}]},{"type":"SECONDARY","title":"The Percentage of Non-vertebral Fractures","description":"The results are expressed as percentage by Kaplan-Meier estimate the percentage of participants with non-vertebral fractures","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":null},{"groupId":"OG001","value":"4.1","spread":null},{"groupId":"OG002","value":"2.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hip Fractures in Osteoporotic Participants Treated With Denosumab Compared to Treatment With Placebo.","description":"The results are expressed as a percentage by Kaplan-Meier estimate.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.5","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":65,"n":475},"commonTop":["Nasopharyngitis","Contusion","Dental caries","Osteoarthritis","Back pain"]}}}